Rilpivirine
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Rilpivirine: Drug Repurposing Evaluation — Insufficient Evidence Pack
One-Sentence Summary
Rilpivirine (DrugBank: DB08864) is an antiretroviral agent belonging to the NNRTI class, used in the treatment of HIV-1 infection. This Evidence Pack does not contain any TxGNN-predicted repurposing indications, and the drug carries no regulatory authorizations in Taiwan. A Hold decision is recommended until prediction outputs and safety documentation are obtained.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in regulatory data |
| Predicted New Indication | No predictions available in this Evidence Pack |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No supporting studies; model output absent |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Taiwan Market Information
No authorized products found for Rilpivirine in the Taiwan regulatory database. Zero licenses are on record.
Safety Considerations
Please refer to the package insert for safety information.
The TFDA package insert query returned a record (see query log ID 4), but warning and contraindication content has not been parsed into this Evidence Pack. Drug interaction data was not found (query log ID 2).
Conclusion and Next Steps
Decision: Hold
Rationale:
The predicted_indications array is empty — there are no TxGNN repurposing candidates to evaluate for this compound. Without a target indication, neither mechanistic relevance, clinical evidence, nor a benefit-risk assessment can be conducted.
To proceed, the following is needed:
- TxGNN output: Re-run TxGNN inference for Rilpivirine (DB08864) and confirm whether any indication scores meet the reporting threshold
- MOA data (DG002 – High severity): Retrieve mechanism of action from DrugBank API to enable mechanistic plausibility analysis
- Safety documentation (DG001 – Blocking): Parse the TFDA package insert PDF already retrieved (query log ID 4) to extract key warnings, contraindications, and special population restrictions before any S1 safety screening
- Target market review: Confirm whether Germany (BfArM) or Taiwan (TFDA) is the intended regulatory jurisdiction for this candidate, and align the Evidence Pack accordingly
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.